Abstract: Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.
Type:
Grant
Filed:
October 4, 2019
Date of Patent:
December 28, 2021
Assignees:
Janssen Vaccines & Prevention B.V., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Dan Barouch, Johanna Schuitemaker, Maria Grazia Pau, Danielle Van Manen, Frank Tomaka, Jennifer Anne Hendriks
Abstract: Described are N332 glycan-dependent antibodies for treating human immunodeficiency virus (HIV) in a subject that is infected with HIV and that is receiving antiretroviral therapy (ART).
Type:
Grant
Filed:
August 8, 2019
Date of Patent:
December 21, 2021
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: Electrical impedance myography (EIM) can be used for assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and modeling one or more impedance metrics as a function of frequency may provide impedance model parameters that can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.
Type:
Application
Filed:
April 12, 2021
Publication date:
November 25, 2021
Applicant:
Beth Israel Deaconess Medical Center, Inc.
Inventors:
Seward B. Rutkove, Benjamin Sanchez Terrones
Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
Type:
Application
Filed:
December 22, 2020
Publication date:
November 25, 2021
Applicants:
The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
Abstract: The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders—including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders—using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.
Type:
Grant
Filed:
March 8, 2018
Date of Patent:
November 16, 2021
Assignees:
Beth Israel Deaconess Medical Center, Inc., President and Fellows of Harvard College
Inventors:
Barbara B. Kahn, Mark A. Herman, Alan Saghatelian, Edwin Homan, Mark M. Yore, Ismail Syed, Pedro M. M. Moraes Vieira
Abstract: Systems and methods for acquiring magnetic resonance imaging (MRI) images of a subject are provided. The method includes performing a pulse sequence to elicit spin echoes, wherein the pulse sequence includes a radio frequency (RF) excitation pulse and a series of RF refocusing pulses that refocus echoes with flip angles in the series of RF refocusing pulses that are varied. The method also includes scaling MRI data associated with each echo by a correction factor that is determined for each echo to create scaled MRI data and that is not the same for all echoes. The method then includes reconstructing an image of the subject using the scaled MRI data.
Type:
Grant
Filed:
March 22, 2018
Date of Patent:
November 2, 2021
Assignee:
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Abstract: Disclosed herein are compounds comprising an electrophilic moiety and rigid moiety for use in modulating an activity of Pin1. The rigid moiety comprises at least one functional group that is capable of forming hydrogen bonds with hydrogen atoms, wherein the electrophilic moiety and the rigid moiety are arranged such that the electrophilic moiety is capable of covalently binding to the Cys113 residue of Pin1, and the rigid moiety is capable of forming hydrogen bonds with the Gln131 and His 157 residues of Pin1. Further disclosed are novel compounds having Formula Id: wherein the dashed line, W, X, Y, Z, Ra-Rc, R1, R2, L1, L2 and n are as defined herein, and libraries comprising such compounds. Further disclosed are methods of identifying a compound capable of modulating an activity of Pin1, by screening a library of compounds.
Type:
Application
Filed:
July 8, 2021
Publication date:
October 28, 2021
Applicants:
Yeda Research and Development Co. Ltd., Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
Inventors:
Nir LONDON, Daniel ZAIDMAN, Christian DUBIELLA, Nathanael S. GRAY, Benika Joan PINCH, Kun Ping LU, Alfred Thomas LOOK, Shuning HE, Xiao Zhen ZHOU, Xiaolan LIAN
Abstract: Disclosed herein are methods and compositions for treating a subject having or at risk of having an HIV infection. Disclosed herein are peptide immunogens and nucleic acids that have epitopes in which mutations are most likely to have deleterious effects on the HIV virus. An algorithm is disclosed for the selection of the epitopes based on the HIV fitness landscape, and it accounts for the effect of coupling mutations.
Type:
Application
Filed:
May 29, 2020
Publication date:
October 14, 2021
Applicants:
Massachusetts Institute of Technology, The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.
Inventors:
Darrell J. Irvine, Dan H. Barouch, Arup K. Chakraborty, Dariusz Murakowski, Bruce D. Walker, John Barton, Andrew Ferguson
Abstract: As described below, the present invention features compositions and methods of treating cancers characterized by the loss of Pten, Zbtb7a/Pokemon, p53, Pml and other tumor suppressors by inhibiting the expression or activity of CXCL5; and methods for identifying therapeutics using a murine platform.
Type:
Application
Filed:
August 29, 2017
Publication date:
September 30, 2021
Applicant:
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
September 28, 2021
Assignees:
Beth Israel Deaconess Medical Center, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer, National Institutes of Health
Inventors:
Kun Ping Lu, Matthew Brian Boxer, Mindy Irene Emily Davis, Rajan Pragani, Min Shen, Anton Momtchilov Simeonov, Shuo Wei, Xiao Zhen Zhou
Abstract: The disclosure relates to the use of A20 to restore glycemic control in a subject in need thereof, for example, a subject having diabetes. This novel approach provides non-insulin based therapy for diabetes.
Type:
Application
Filed:
August 15, 2017
Publication date:
September 16, 2021
Applicant:
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Inventors:
Christiane Ferran, Cleide Da Silva, Alessandra Mele
Abstract: Methods of treating ischemic tissue injury or kidney disease, e.g., delayed graft function, that include administering a Nicotinamide adenine dinucleotide (NAD)/niacinamide (NAM) pathway agonist.
Type:
Grant
Filed:
February 21, 2017
Date of Patent:
September 14, 2021
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: As described below, the present invention features compositions and methods of treating cancers characterized by the loss of Pten, Zbtb7a/Pokemon, p53, Pml and other tumor suppressors by inhibiting the expression or activity of CXCL17; and methods for identifying CXCL17 antagonists using a murine platform.
Type:
Application
Filed:
August 29, 2017
Publication date:
September 9, 2021
Applicant:
BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders associated with mast cells. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more diseases and disorders associated with mast cells.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
August 10, 2021
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.
Type:
Application
Filed:
June 13, 2019
Publication date:
August 5, 2021
Applicants:
DANA-FARBER CANCER INSTITUTE, INC., BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Inventors:
Nathanael GRAY, Benika PINCH, Sirano DHE-PAGANON, Hyuk-Soo SEO, Chris BROWNE, Jarrod MARTO, Zainab DOCTOR, Kun Ping LU, Xiao ZHOU, Shingo KOZONO, Xiaolan LIAN
Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.
Type:
Application
Filed:
April 24, 2019
Publication date:
August 5, 2021
Applicants:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Beth Israel Deaconess Medical Center, Inc., The Government of the United States as Represented by the Secretary of the Army
Inventors:
Shelly Krebs, Gina Donofrio, Vincent Dussupt, Kayvon Modjarrad, Dan Barouch, Richard G. Jarman, III, Nelson L. Michael, Gordon Joyce
Abstract: Methods for detecting angiopoietin-2 (Angpt-2) and/or thrombospondin-2 (Tsp-2) in a sample involve obtaining or having obtained a blood or plasma sample from a subject; and detecting Angpt-2 and Tsp-2 in the sample. Detecting can involve performing an assay to determine whether the sample includes Angpt-2 and/or Tsp-2 or elevated levels of Angpt-2 and/or Tsp-2. Elevated levels are indicative of acute heart failure.
Type:
Grant
Filed:
July 25, 2018
Date of Patent:
August 3, 2021
Assignees:
Vanderbilt University, Beth Israel Deaconess Medical Center, Inc.
Inventors:
Thomas J. Wang, Deepak K. Gupta, Quinn S. Wells, Robert E. Gerszten
Abstract: The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
Type:
Grant
Filed:
November 1, 2018
Date of Patent:
July 13, 2021
Assignee:
Beth Israel Deaconess Medical Center, Inc.
Abstract: In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
Type:
Application
Filed:
August 23, 2019
Publication date:
June 17, 2021
Applicant:
Beth Israel Deaconess Medical Center, Inc.
Inventors:
Robert Flaumenhaft, David Barrios, Secil Koseoglu
Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
Type:
Grant
Filed:
November 30, 2016
Date of Patent:
June 8, 2021
Assignees:
Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.